Advances in PGD2/PTGDR2 Signaling Pathway in Tumors: A Review

Overview

Journal Biomol Biomed

Specialties Biochemistry
General Medicine

Date 2024 May 5

PMID 38704736

Authors

Hengjin Tian

Kunpeng Ge

Lulu Wang

Peiyao Gao

Amin Chen

Feifan Wang

Fangzheng Guo

Fengchao Wang

Qiang Zhang

Affiliations

Soon will be listed here.

Abstract

Studies have shown that the prostaglandin (PG) family acts as an allergic inflammatory mediator in malignant diseases. Furthermore, prostaglandin E2 (PGE2) and its related receptors, as well as the prostaglandin D2 (PGD2)/PGD2 receptor (PTGDR2), play irreplaceable roles in tumorigenesis and anti-tumor therapy. Several experiments have demonstrated that PGD2 signaling through PTGDR2 not only directly inhibits cancer cell survival, proliferation, and migration but also reduces resistance toward conventional chemotherapeutic agents. Recent studies from our and other laboratories have shown that PGD2, its ligands, and related metabolites can significantly alter the tumor microenvironment (TME) by promoting the secretion of chemokines and cytokines, thereby inhibiting tumor progression. Additionally, reduced PGD2 expression has been associated with poor prognosis in patients with gastric, breast, lung, and pancreatic cancers, validating the preclinical findings and their clinical relevance. This review focuses on the current understanding of PGD2/PTGDR2 expression patterns and biological activity in cancer, proposing questions to guide the assessment of PGD2 and its receptors as potential targets for effective cancer therapies.

References

Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Lonnroth C . Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol. 2007; 46(8):1107-12. DOI: 10.1080/02841860701403061. View

Jandl K, Heinemann A . The therapeutic potential of CRTH2/DP2 beyond allergy and asthma. Prostaglandins Other Lipid Mediat. 2017; 133:42-48. PMC: 7612073. DOI: 10.1016/j.prostaglandins.2017.08.006. View

Fujitani Y, Kanaoka Y, Aritake K, Uodome N, Urade Y . Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol. 2001; 168(1):443-9. DOI: 10.4049/jimmunol.168.1.443. View

Mochizuki M, Ishii Y, Itoh K, Iizuka T, Morishima Y, Kimura T . Role of 15-deoxy delta(12,14) prostaglandin J2 and Nrf2 pathways in protection against acute lung injury. Am J Respir Crit Care Med. 2005; 171(11):1260-6. DOI: 10.1164/rccm.200406-755OC. View

Dash P, Ghatak S, Topi G, Satapathy S, Ek F, Hellman K . High PGD receptor 2 levels are associated with poor prognosis in colorectal cancer patients and induce VEGF expression in colon cancer cells and migration in a zebrafish xenograft model. Br J Cancer. 2021; 126(4):586-597. PMC: 8854381. DOI: 10.1038/s41416-021-01595-4. View

Misawa K, Imai A, Kanazawa T, Mima M, Yamada S, Mochizuki D . G Protein-Coupled Receptor Genes, PTGDR1, PTGDR2, and PTGIR, Are Candidate Epigenetic Biomarkers and Predictors for Treated Patients with HPV-Associated Oropharyngeal Cancer. Microorganisms. 2020; 8(10). PMC: 7601742. DOI: 10.3390/microorganisms8101504. View

Spik I, Brenuchon C, Angeli V, Staumont D, Fleury S, Capron M . Activation of the prostaglandin D2 receptor DP2/CRTH2 increases allergic inflammation in mouse. J Immunol. 2005; 174(6):3703-8. DOI: 10.4049/jimmunol.174.6.3703. View

Sheng H, Shao J, Morrow J, Beauchamp R, DuBois R . Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58(2):362-6. View

Kostenis E, Ulven T . Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med. 2006; 12(4):148-58. DOI: 10.1016/j.molmed.2006.02.005. View

10.

Wang P, Fu Y, Chen Y, Li Q, Hong Y, Liu T . Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome. Biomed Res Int. 2020; 2020:4029062. PMC: 7709499. DOI: 10.1155/2020/4029062. View

11.

Murata T, Aritake K, Matsumoto S, Kamauchi S, Nakagawa T, Hori M . Prostagladin D2 is a mast cell-derived antiangiogenic factor in lung carcinoma. Proc Natl Acad Sci U S A. 2011; 108(49):19802-7. PMC: 3241753. DOI: 10.1073/pnas.1110011108. View

12.

Genovese T, Cuzzocrea S, Di Paola R, Mazzon E, Mastruzzo C, Catalano P . Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J. 2005; 25(2):225-34. DOI: 10.1183/09031936.05.00049704. View

13.

Hashimoto K, Ethridge R, Evers B . Peroxisome proliferator-activated receptor gamma ligand inhibits cell growth and invasion of human pancreatic cancer cells. Int J Gastrointest Cancer. 2003; 32(1):7-22. DOI: 10.1385/IJGC:32:1:7. View

14.

Joo M, Sadikot R . PGD synthase and PGD2 in immune resposne. Mediators Inflamm. 2012; 2012:503128. PMC: 3389719. DOI: 10.1155/2012/503128. View

15.

Mesquita-Santos F, Vieira-de-Abreu A, Calheiros A, Figueiredo I, Castro-Faria-Neto H, Weller P . Cutting edge: prostaglandin D2 enhances leukotriene C4 synthesis by eosinophils during allergic inflammation: synergistic in vivo role of endogenous eotaxin. J Immunol. 2006; 176(3):1326-30. DOI: 10.4049/jimmunol.176.3.1326. View

16.

Yoshida T, Ohki S, Kanazawa M, Mizunuma H, Kikuchi Y, Satoh H . Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer. Surg Today. 1998; 28(7):740-5. DOI: 10.1007/BF02484622. View

17.

Chen E, Smyth E . COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins Other Lipid Mediat. 2011; 96(1-4):14-20. PMC: 4031099. DOI: 10.1016/j.prostaglandins.2011.08.005. View

18.

Alves M, Soares do Amaral N, Marchi F, Silva F, Balieiro Anastacio da Costa A, Carvalho K . Prostaglandin D2 expression is prognostic in high‑grade serous ovarian cancer. Oncol Rep. 2019; 41(4):2254-2264. DOI: 10.3892/or.2019.6984. View

19.

Hinshaw L, Solomon L, Erdos E, REINS D, Gunter B . Effects of acetylsalicylic acid on the canine response to endotoxin. J Pharmacol Exp Ther. 1967; 157(3):665-71. View

20.

Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, Bellingan G . Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci U S A. 2007; 104(52):20979-84. PMC: 2409252. DOI: 10.1073/pnas.0707394104. View